企业QQ
官方微信
MedKooCat#:202030
Name:Glutathionedisulfide(NOV-002)
CAS#:27025-41-8
ChemicalFormula:C20H32N6O12S2
ExactMass:612.15196
MolecularWeight:612.63
ElementalAnalysis:C,39.21;H,5.26;N,13.72;O,31.34;S,10.47
Synonym:NOV002;NOV-002;NOV002;glutathionedisulfide;GSSG;oxidizedglutathione;glutathionedimer;Gluthoxim;Glutoxim.
IUPAC/ChemicalName:(2S,2S)-5,5-(((2R,2R)-disulfanediylbis(1-((carboxymethyl)amino)-1-oxopropane-3,2-diyl))bis(azanediyl))bis(2-amino-5-oxopentanoicacid)
InChiKey:YPZRWBKMTBYPTK-XOGOEWOHSA-N
InChiCode:InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12?/m0/s1
SMILESCode:O=C(NCC(O)=O)[C@@H](NC(CC[C@H](N)C(O)=O)=O)CSSC[C@H](NC(CC[C@H](N)C(O)=O)=O)C(NCC(O)=O)=O
1:GumireddyK,LiA,CaoL,YanJ,LiuL,XuX,PazolesC,HuangQ.NOV-002,AGlutathioneDisulfideMimetic,SuppressesTumorCellInvasionandMetastasis.JCarcinogMutagen.2013Apr30;2013.pii:S7-002.PubMedPMID:24377058;PubMedCentralPMCID:PMC3872994.
2:GrekCL,TownsendDM,UysJD,ManevichY,CokerWJ3rd,PazolesCJ,TewKD.S-glutathionylatedserineproteinaseinhibitorsasplasmabioMarkersinassessingresponsetoredox-modulatingdrugs.CancerRes.2012May1;72(9):2383-93.doi:10.1158/0008-5472.CAN-11-4088.Epub2012Mar8.PubMedPMID:22406622.
3:Diaz-MonteroCM,WangY,ShaoL,FengW,ZidanAA,PazolesCJ,MonteroAJ,ZhouD.TheglutathionedisulfidemimeticNOV-002inhibitscyclophosphamide-inducedhematopoieticandimmunesuppressionbyreducingoxidativestress.FreeRadicBiolMed.2012May1;52(9):1560-8.doi:10.1016/j.freeradbiomed.2012.02.007.Epub2012Feb15.PubMedPMID:22343421;PubMedCentralPMCID:PMC3341494.
4:MonteroAJ,Diaz-MonteroCM,DeutschYE,HurleyJ,KoniarisLG,RumboldtT,YasirS,JordaM,Garret-MayerE,AvisarE,SlingerlandJ,SilvaO,WelshC,SchuhwerkK,SeoP,PegramMD,GlückS.Phase2studyofneoadjuvanttreatmentwithNOV-002incombinationwithdoxorubicinandcyclophosphamidefollowedbydocetaxelinpatientswithHER-2negativeclinicalstageII-IIIcbreastcancer.BreastCancerResTreat.2012Feb;132(1):215-23.doi:10.1007/s10549-011-1889-0.Epub2011Dec3.PubMedPMID:22138748;PubMedCentralPMCID:PMC3697917.
5:MonteroAJ,JassemJ.Cellularredoxpathwaysasatherapeutictargetinthetreatmentofcancer.Drugs.2011Jul30;71(11):1385-96.doi:10.2165/11592590-000000000-00000.Review.PubMedPMID:21812504.
6:SönmezMF,SavranlarY.LettertotheeditorregardingthearticlebyJendernyetal.BiomedPharmacother.2011Aug;65(5):385.doi:10.1016/j.biopha.2011.04.002.Epub2011Jun28.PubMedPMID:21782378.
7:UysJD,ManevichY,DevaneLC,HeL,GarretTE,PazolesCJ,TewKD,TownsendDM.PreclinicalpharmacokineticanalysisofNOV-002,aglutathionedisulfidemimetic.BiomedPharmacother.2010Sep;64(7):493-8.doi:10.1016/j.biopha.2010.01.003.Epub2010Feb24.PubMedPMID:20359856;PubMedCentralPMCID:PMC2921589.
8:JendernyS,LinH,GarrettT,TewKD,TownsendDM.Protectiveeffectsofaglutathionedisulfidemimetic(NOV-002)againstcisplatininducedkidneytoxicity.BiomedPharmacother.2010Jan;64(1):73-6.doi:10.1016/j.biopha.2009.09.009.Epub2009Oct17.PubMedPMID:19896793;PubMedCentralPMCID:PMC3388846.
9:TownsendDM,TewKD.Pharmacologyofamimeticofglutathionedisulfide,NOV-002.BiomedPharmacother.2009Feb;63(2):75-8.doi:10.1016/j.biopha.2008.08.019.Epub2008Sep17.PubMedPMID:18851905;PubMedCentralPMCID:PMC2657662.
10:TownsendDM,PazolesCJ,TewKD.NOV-002,amimeticofglutathionedisulfide.ExpertOpinInvestigDrugs.2008Jul;17(7):1075-83.doi:10.1517/13543784.17.7.1075.PubMedPMID:18549343.
11:TownsendDM,HeL,HutchensS,GarrettTE,PazolesCJ,TewKD.NOV-002,aglutathionedisulfidemimetic,asamodulatorofcellularredoxbalance.CancerRes.2008Apr15;68(8):2870-7.doi:10.1158/0008-5472.CAN-07-5957.PubMedPMID:18413755;PubMedCentralPMCID:PMC3397193.
12:TownsendDM,FindlayVL,TewKD.GlutathioneS-transferasesasregulatorsofkinasepathwaysandanticancerdrugtargets.MethodsEnzymol.2005;401:287-307.Review.PubMedPMID:16399394.